NCT07539883 Effect of oXiris Hemofilter Use in Septic Shock: A Multicenter Retrospective Cohort Study
| NCT ID | NCT07539883 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Seoul National University Bundang Hospital |
| Condition | Septic Shock |
| Study Type | OBSERVATIONAL |
| Enrollment | 360 participants |
| Start Date | 2026-01-22 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 360 participants in total. It began in 2026-01-22 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to evaluate the clinical effectiveness of the oXiris® hemofilter in patients with septic shock and acute kidney injury (AKI) requiring continuous renal replacement therapy (CRRT). While some studies suggest that oXiris® may improve hemodynamic stability by removing endotoxins and cytokines, its impact on survival remains inconsistent.To provide more reliable causal evidence, this multicenter retrospective cohort study utilizes a Target Trial Emulation (TTE) approach. The study will compare patients treated with the oXiris® filter to those treated with standard CRRT filters, focusing on in-hospital mortality and other clinical outcomes such as fluid balance and vasopressor requirements.
Eligibility Criteria
Inclusion Criteria: * Adults aged 19 years or older. * Admitted to the ICU with septic shock (Sepsis-3 criteria) between March 2021 and August 2025. * Required Continuous Renal Replacement Therapy (CRRT) due to acute kidney injury (AKI). Exclusion Criteria: * Death or withdrawal of life-sustaining therapy within 48 hours of ICU admission. * Patients with End-Stage Renal Disease (ESRD). * Patients with missing critical covariates.
Contact & Investigator
Sung Yoon Lim, MD.PhD
PRINCIPAL INVESTIGATOR
Seoul National University Bundang Hospital
Frequently Asked Questions
Who can join the NCT07539883 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, studying Septic Shock. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07539883 currently recruiting?
Yes, NCT07539883 is actively recruiting participants. Contact the research team at nucleon727@snu.ac.kr for enrollment information.
Where is the NCT07539883 trial being conducted?
This trial is being conducted at Seongnam-si, South Korea.
Who is sponsoring the NCT07539883 clinical trial?
NCT07539883 is sponsored by Seoul National University Bundang Hospital. The principal investigator is Sung Yoon Lim, MD.PhD at Seoul National University Bundang Hospital. The trial plans to enroll 360 participants.